Skip Navigation


The Computer Journal Advance Access first published online on April 4, 2008
This version published online on April 9, 2008
The Computer Journal, doi:10.1093/comjnl/bxn021
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
bxn021v3    most recent
bxn021v2
bxn021v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Gammerman, A.
Right arrow Articles by Jacobs, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of The British Computer Society. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Serum Proteomic Abnormality Predating Screen Detection of Ovarian Cancer

Alex Gammerman1,5,*, Volodya Vovk1, Brian Burford1, Ilia Nouretdinov1, Zhiyuan Luo1, Alexey Chervonenkis1, Mike Waterfield2, Rainer Cramer2,3, Paul Tempst4, Josep Villanueva4, Musarat Kabir5, Stephane Camuzeaux5, John Timms5, Usha Menon5 and Ian Jacobs5

1 Computer Learning Research Centre, Royal Holloway, University of London, UK
2 Ludwig Institute for Cancer Research, University College London, UK
3 BioCentre and Department of Chemistry, University of Reading, UK
4 Memorial Sloan-Kettering Cancer Center, New York, USA
5 Institute for Women's Health, University College London, UK

* Corresponding author: alex{at}cs.rhul.ac.uk

Received 19 November 2007; revised 20 January 2008

Ovarian cancer is characterized by vague, non-specific symptoms, advanced stage at diagnosis and poor overall survival. A nested case control study was undertaken on stored serial serum samples from women who developed ovarian cancer and healthy controls (matched for serum processing and storage conditions as well as attributes such as age) in a pilot randomized controlled trial of ovarian cancer screening. The unique feature of this study is that the women were screened for up to 7 years. The serum samples underwent prefractionation using a reversed-phase batch extraction protocol prior to MALDI-TOF MS data acquisition. Our exploratory analysis shows that combining a single MS peak with CA125 allows statistically significant discrimination at the 5% level between cases and controls up to 12 months in advance of the original diagnosis of ovarian cancer. Such combinations work much better than a single peak or CA125 alone. This paper demonstrates that mass spectra from the low molecular weight serum proteome carry information useful for early detection of ovarian cancer. The next step is to identify the specific biomarkers that make early detection possible.

Key Words: bioinformatics • biomarkers • CA125 • human serum proteome • mass spectra • ovarian cancer

The originally published version of this paper was incorrect.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.